Brief: Radiopharm Theranostics Enters Into Strategic Collaboration With Lantheus
04/08/2022 02:06
Aug 4 (Reuters) - Radiopharm Theranostics Ltd RAD.AX :
* ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND
ASSUMES
PD-L1 LICENSING AGREEMENT FROM NANOMAB
* ACQUIRED FROM NANOMAB IMAGING RIGHTS OF NM-01 FOR
STRATEGIC
CHINESE MARKET AND WORLDWIDE IP RIGHTS FOR ANY THERAPEUTIC USE
Source text for Eikon: ID:nASX3PSBqC
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%